Exagen inc. and queen mary university of london announce exclusive license and collaboration to develop novel patented molecular signatures for rheumatoid arthritis biologic therapeutic selection

San diego, jan. 09, 2022 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, and queen mary university of london, announced today the execution of a research collaboration and exclusive license agreement. the collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on rna expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (ra) patients. both parties will contribute to the development of the patent-pending assays, leading to the commercialization of novel molecular assays that segment patients according to gene expression in their synovial tissue biopsies.
XGN Ratings Summary
XGN Quant Ranking